Search results
Author(s):
Carmen Lara-Romero
,
Manuel Romero-Gómez
Added:
11 months ago
Author(s):
Marc P Bonaca
Added:
5 months ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,…
View more
Author(s):
Sheila Gato
,
Vanessa García-Fernández
,
Antonio Gil-Gómez
,
et al
Added:
1 year ago
Cardiovascular Risk in NAFLD
Author(s):
Paula Luque-Linero
,
Luis Castilla-Guerra
Added:
1 year ago
Article
Remnant Lipoproteins and ASCVD
Author(s):
Mohanad Gabani
,
Michael D Shapiro
,
Peter P Toth
Added:
1 year ago
Article
Raif Tawakol
Job title: Director
Author
Andrew Mente
Job title: Associate Professor – Department of Health Research Methods, Evidence, and Impact (HEI)
Author
Author(s):
Carlos Millán-Rodríguez
,
Carlos Palacios Castelló
,
María de Regla Caballero-Valderrama
,
et al
Added:
1 year ago
Author(s):
Samuel S Engel
Added:
1 year ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants…
View more
e-SPACE CRM 2024 - Day 2
Author(s):
Antonio Ceriello
,
Ileana L Piña
,
Gianluigi Savarese
,
et al
Start date:
Mar 23, 2024
Broadcast